BSW Wealth Partners’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-9,099
Closed -$628K 346
2025
Q2
$628K Sell
9,099
-956
-10% -$65K 0.09% 133
2025
Q1
$698K Buy
10,055
+759
+8% +$62.7K 0.11% 117
2024
Q4
$800K Buy
9,296
+213
+2% +$23K 0.12% 108
2024
Q3
$1.08M Buy
9,083
+369
+4% +$49.2K 0.16% 73
2024
Q2
$1.24M Buy
8,714
+42
+0.5% +$5.57K 0.2% 64
2024
Q1
$1.11M Sell
8,672
-1,012
-10% -$120K 0.19% 69
2023
Q4
$1M Sell
9,684
-42
-0.4% -$4.15K 0.2% 71
2023
Q3
$884K Sell
9,726
-336
-3% -$29.6K 0.2% 70
2023
Q2
$814K Buy
10,062
+18
+0.2% +$1.47K 0.17% 77
2023
Q1
$799K Sell
10,044
-194
-2% -$13.8K 0.16% 90
2022
Q4
$693K Buy
10,238
+684
+7% +$40.1K 0.15% 101
2022
Q3
$476K Buy
+9,554
New +$512K 0.12% 123
2021
Q1
Sell
-7,454
Closed -$260K 223
2020
Q4
$260K Buy
7,454
+858
+13% +$29.7K 0.08% 138
2020
Q3
$229K Buy
+6,596
New +$220K 0.09% 122

Other funds holding NVO

BSW Wealth Partners's NVO Position: Q3 2025 in Review

BSW Wealth Partners sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 9,099 shares — an estimated $628K sold.

BSW Wealth Partners first reported a position in NVO in Q3 2020 and held it in 14 quarters. The position peaked at $1.24M in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • BSW Wealth Partners reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • BSW Wealth Partners sold 9,099 Novo Nordisk shares in Q3 2025, an estimated $628K.
  • BSW Wealth Partners first reported a position in Novo Nordisk in Q3 2020 and held it in 14 quarters.
  • BSW Wealth Partners's Novo Nordisk position peaked at $1.24M in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on BSW Wealth Partners's 13F filing for Q3 2025, filed 15 Oct 2025.